Whether NR2F2 and FOXC1 influence their respective binding in TNBC remains to be determined, but the possibility of using the NR2F2-inhibitor to disrupt the interaction with FOXC1 in TNBC presents a potential targeted-therapy approach for basal-like breast cancer. This evidence concerns the gene FOXC1 and breast carcinoma.